Novartis Slapped With New $49m Fine For Korea ‘Rebates’
Executive Summary
Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number of its drugs under a new ministerial action related to illegal "rebate" payments made to prescribers.
You may also be interested in...
Korea Revises Rules To Curb Rebate Activities, Improve Ethics
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
More Action Against Novartis As Korea FTC Issues Fine For Unfair Promotion
In another blow to Novartis, South Korea's Fair Trade Commission has imposed a fine on the South Korean subsidiary of the Swiss firm for carrying out unfair promotion of its products at meetings for medical professionals.